Sodium-glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective

André J Scheen¹

Affiliations

Affiliation

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, B-4000 Liège, Belgium; Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium. Electronic address: andre.scheen@chuliege.be.

PMID: 39250920
DOI: 10.1016/S2213-8587(24)00230-4

Comment

Sodium-glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective

André J Scheen. Lancet Diabetes Endocrinol. 2024 Oct.

. 2024 Oct;12(10):685-687.

doi: 10.1016/S2213-8587(24)00230-4. Epub 2024 Sep 6.

Author

André J Scheen¹

Affiliation

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, B-4000 Liège, Belgium; Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium. Electronic address: andre.scheen@chuliege.be.

PMID: 39250920
DOI: 10.1016/S2213-8587(24)00230-4

No abstract available

PubMed Disclaimer

Conflict of interest statement

AJS declares consulting fees from Eli Lilly, Astra Zeneca, and Boehringer Ingelheim; and honoraria for lectures or presentations from Novo Nordisk, Eli Lilly, Astra Zeneca, Boehringer Ingelheim, Menarini, and Merck Sharp & Dome.

Comment on

Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial.
Kosiborod MN, Windsor SL, Vardeny O, Berger JS, Reynolds HR, Boumakis S, Althouse AD, Solomon SD, Bhatt AS, Peikert A, Luther JF, Leifer ES, Kindzelski AL, Cushman M, Ng Gong M, Kornblith LZ, Khatri P, Kim KS, Baumann Kreuziger L, Javaheri A, Carpio C, Wahid L, Lopez-Sendon Moreno J, Alonso A, Ho MQ, Lopez-Sendon J, Lopes RD, Curtis JL, Kirwan BA, Geraci MW, Neal MD, Hochman JS; ACTIV-4a Investigators. Kosiborod MN, et al. Lancet Diabetes Endocrinol. 2024 Oct;12(10):725-734. doi: 10.1016/S2213-8587(24)00218-3. Epub 2024 Sep 6. Lancet Diabetes Endocrinol. 2024. PMID: 39250922 Clinical Trial.
Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials.
Vale C, Godolphin PJ, Fisher D, Horby PW, Kosiborod MN, Hochman JS, Webster K, Higgins JPT, Althouse AD, Berwanger O, Furtado RHM, Gasparyan SB, Haynes R, Koch GG, Landray M, Leifer E, Marshall J, Murthy S, Neal MD, Staplin N, Diaz J, Sterne JAC, Shankar-Hari M; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Vale C, et al. Lancet Diabetes Endocrinol. 2024 Oct;12(10):735-747. doi: 10.1016/S2213-8587(24)00219-5. Epub 2024 Sep 6. Lancet Diabetes Endocrinol. 2024. PMID: 39250923

References

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Sodium-glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective

Affiliation

Sodium-glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective

Author

Affiliation

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources